Bluebird Bio Resumes Marketing Of Gene Therapy Zynteglo For β-Thalassaemia In Europe – TIF
Bluebird Bio Withdraws Zynteglo From Germany Over Pricing :: Pink Sheet
FDA Approves Bluebird's $2.8 Million Gene Therapy for Rare Blood Disease - WSJ
Bluebird bio's gene therapy Zynteglo could have high price tag defense in beta thalassemia - Pharmaceutical Technology
FDA approves bluebird bio's Zynteglo gene therapy for beta thalassemia; shares up 7% | Seeking Alpha
bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies - Pharmaceutical Technology
Bluebird bio announces 1st commercial launch of ZYNTEGLO™in Germany – TIF
ICER Draft Evidence Report on Bluebird Gene Therapy Zynteglo Finds It Provides Value at $2.1 Million - Global Genes
SEC Filing - bluebird bio, Inc.
Somerville gene therapy firm bluebird bio nabs win with first FDA approval following split - Boston Business Journal
bluebird claims first approval for gene therapy Zynteglo in EU -
bluebird bio Launches Gene Therapy for Severe Blood Disorder in Germany | North Carolina Biotechnology Center
SEC Filing - bluebird bio, Inc.
bluebird bio gets CHMP nod for gene therapy Zynteglo | Pharmaphorum
Bluebird puts €1.57m price on gene therapy Zynteglo - PMLiVE
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions | Business Wire
Bluebird bio sets €1.6M price tag for rare blood disease gene therapy | S&P Global Market Intelligence
Patient group echoes bluebird bio stance over Zynteglo UK funding snub
NICE turns down bluebird bio's gene therapy Zynteglo - PMLiVE
Zynteglo: Gene Therapy for Beta-thalassemia • BioPharma Media
Bluebird wins U.S. approval for gene therapy for beta thalassemia - STAT
ICER's Favorable Assessment Of Bluebird Bio's Gene Therapy Zynteglo May Have Important Pricing And Reimbursement Implications
ZYNTEGLO® (betibeglogene autotemcel)
At $2.8 Million, Beti-cel Is a Canary in the Drug Cost Coal Mine
